Immunome Prices 18.625M Shares at $21.50, Raising Approximately $400 Million
- Significant Fundraising: Immunome announced the pricing of 18.625 million shares at $21.50 each, raising approximately $400 million, which will provide crucial funding for its cancer therapy development and accelerate clinical project advancements.
- Underwriter Selection: The offering is managed by Leerink Partners, J.P. Morgan, TD Cowen, Goldman Sachs, and Guggenheim Securities, reflecting strong market confidence in Immunome and potentially enhancing its reputation in the biotechnology sector.
- Additional Share Option: Immunome granted underwriters a 30-day option to purchase an additional 2.79375 million shares, which, if exercised, could further increase total proceeds and enhance the company's financial flexibility to meet future R&D needs.
- Closing Timeline: The offering is expected to close on December 18, 2025, subject to customary closing conditions, providing investors with a clear timeline that may increase market interest in the company.
Trade with 70% Backtested Accuracy
Analyst Views on IMNM
About IMNM
About the author
Market Overview: Energy Stocks Show Strength
- Market Performance Overview: Last week, the S&P 500 gained 0.34%, while the Nasdaq and Dow Jones fell by 0.17% and 0.42%, respectively, indicating market divergence and suggesting that investors should remain cautious as February approaches, a historically weaker month.
- Energy Stock Potential: Energy Fuels Inc. (UUUU), focused on uranium mining, reported $24.9 million in revenue last quarter with no earnings, yet its astronomical Price-to-Sales ratio of 63.50 reflects strong market expectations for future growth, with an anticipated 81% upside potential.
- Technical Indicator Analysis: UUUU is forming a saucer pattern, and if it breaks above the resistance zone, it could trigger a new upward phase, making the $18.50 to $19.00 support level critical for investors to monitor.
- Market Volatility Warning: Despite the S&P 500 hitting an all-time high last week, the Nasdaq failed to break out, suggesting potential volatility ahead; investors should seize buying opportunities, particularly before the upcoming Federal Reserve meeting.
IMNM Options Analysis: Put Contract Offers 27.5% YieldBoost
- Put Contract Yield: The $20.00 put contract for IMNM has a current bid of $5.50, and if an investor sells it, they commit to buying shares at $20.00, resulting in a cost basis of $14.50, making it an attractive alternative to the current price of $20.16.
- Expiration Worthless Probability: The odds of the put contract expiring worthless are 75%, and if it does, the premium would yield a 27.5% return on cash commitment, or 13.6% annualized, highlighting the strategy's potential appeal.
- Call Contract Returns: The $22.00 call contract has a current bid of $6.50, and if an investor buys IMNM shares at $20.16 and sells this call, they could achieve a total return of 41.37% if the stock is called away at January 2028 expiration, indicating strong profit potential.
- Call Contract Expiration Worthless Probability: The call contract has a 28% chance of expiring worthless, allowing investors to keep both their shares and the premium collected, with an additional return of 32.24%, or 15.95% annualized, further enhancing the investment's attractiveness.
Insider Buying Update for Friday, December 19: IMNM and S
Immunome Insider Purchase: Immunome's CEO, Clay B. Siegall, bought 46,511 shares of IMNM for $999,986 at $21.50 each, following previous investments totaling $2.16M at an average of $7.53 per share.
SentinelOne Insider Purchase: Director Mark S. Peek of SentinelOne purchased 40,000 shares at $14.89 each for a total of $595,600, while the stock is currently trading lower at $14.61.
Market Performance: Immunome's stock rose approximately 7.9% on Friday, while SentinelOne's stock saw a slight increase of 0.3%.
Disclaimer: The views expressed in the report are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
Initial Week of IMNM Options Trading for February 2026
Put Contract Overview: The $18.00 put contract has a bid of 20 cents, allowing investors to buy shares at a cost basis of $17.80, which is a 12% discount from the current price of $20.45. There is a 70% chance the contract may expire worthless, offering a potential 1.11% return on cash commitment.
Call Contract Overview: The $21.00 call contract has a bid of $1.55, enabling investors to sell shares at that price, which represents a 3% premium over the current stock price. If the contract expires worthless, investors could keep both the shares and the premium, resulting in a 7.58% additional return.
Volatility Insights: The implied volatility for the put contract is 118%, while the call contract has an implied volatility of 99%. The actual trailing twelve-month volatility is calculated at 78%.
YieldBoost Concept: The article discusses the concept of YieldBoost, highlighting potential returns from both put and call contracts, and emphasizes the importance of tracking odds and trading history for informed investment decisions.
Immunome Prices 18.625M Share Offering at $21.50, Raising Approximately $400 Million
- Significant Fundraising: Immunome announced the pricing of 18.625 million shares at $21.50 each, raising approximately $400 million, which will enhance the company's financial strength to support its cancer therapy development.
- Underwriter Selection: The offering is managed by Leerink Partners, J.P. Morgan, TD Cowen, Goldman Sachs, and Guggenheim Securities, reflecting strong market confidence and support for Immunome.
- Additional Share Option: Immunome granted underwriters a 30-day option to purchase an additional 2.79375 million shares, potentially increasing total fundraising and enhancing the company's financial flexibility.
- Expected Closing Date: The offering is anticipated to close on December 18, 2025, subject to customary closing conditions, which will provide funding to accelerate the clinical development of its innovative therapies.
Immunome Prices 18.625M Shares at $21.50, Raising Approximately $400 Million
- Significant Fundraising: Immunome announced the pricing of 18.625 million shares at $21.50 each, raising approximately $400 million, which will provide crucial funding for its cancer therapy development and accelerate clinical project advancements.
- Underwriter Selection: The offering is managed by Leerink Partners, J.P. Morgan, TD Cowen, Goldman Sachs, and Guggenheim Securities, reflecting strong market confidence in Immunome and potentially enhancing its reputation in the biotechnology sector.
- Additional Share Option: Immunome granted underwriters a 30-day option to purchase an additional 2.79375 million shares, which, if exercised, could further increase total proceeds and enhance the company's financial flexibility to meet future R&D needs.
- Closing Timeline: The offering is expected to close on December 18, 2025, subject to customary closing conditions, providing investors with a clear timeline that may increase market interest in the company.
Market Overview: Energy Stocks Show Strength
- Market Performance Overview: Last week, the S&P 500 gained 0.34%, while the Nasdaq and Dow Jones fell by 0.17% and 0.42%, respectively, indicating market divergence and suggesting that investors should remain cautious as February approaches, a historically weaker month.
- Energy Stock Potential: Energy Fuels Inc. (UUUU), focused on uranium mining, reported $24.9 million in revenue last quarter with no earnings, yet its astronomical Price-to-Sales ratio of 63.50 reflects strong market expectations for future growth, with an anticipated 81% upside potential.
- Technical Indicator Analysis: UUUU is forming a saucer pattern, and if it breaks above the resistance zone, it could trigger a new upward phase, making the $18.50 to $19.00 support level critical for investors to monitor.
- Market Volatility Warning: Despite the S&P 500 hitting an all-time high last week, the Nasdaq failed to break out, suggesting potential volatility ahead; investors should seize buying opportunities, particularly before the upcoming Federal Reserve meeting.
IMNM Options Analysis: Put Contract Offers 27.5% YieldBoost
- Put Contract Yield: The $20.00 put contract for IMNM has a current bid of $5.50, and if an investor sells it, they commit to buying shares at $20.00, resulting in a cost basis of $14.50, making it an attractive alternative to the current price of $20.16.
- Expiration Worthless Probability: The odds of the put contract expiring worthless are 75%, and if it does, the premium would yield a 27.5% return on cash commitment, or 13.6% annualized, highlighting the strategy's potential appeal.
- Call Contract Returns: The $22.00 call contract has a current bid of $6.50, and if an investor buys IMNM shares at $20.16 and sells this call, they could achieve a total return of 41.37% if the stock is called away at January 2028 expiration, indicating strong profit potential.
- Call Contract Expiration Worthless Probability: The call contract has a 28% chance of expiring worthless, allowing investors to keep both their shares and the premium collected, with an additional return of 32.24%, or 15.95% annualized, further enhancing the investment's attractiveness.
Insider Buying Update for Friday, December 19: IMNM and S
Immunome Insider Purchase: Immunome's CEO, Clay B. Siegall, bought 46,511 shares of IMNM for $999,986 at $21.50 each, following previous investments totaling $2.16M at an average of $7.53 per share.
SentinelOne Insider Purchase: Director Mark S. Peek of SentinelOne purchased 40,000 shares at $14.89 each for a total of $595,600, while the stock is currently trading lower at $14.61.
Market Performance: Immunome's stock rose approximately 7.9% on Friday, while SentinelOne's stock saw a slight increase of 0.3%.
Disclaimer: The views expressed in the report are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
Initial Week of IMNM Options Trading for February 2026
Put Contract Overview: The $18.00 put contract has a bid of 20 cents, allowing investors to buy shares at a cost basis of $17.80, which is a 12% discount from the current price of $20.45. There is a 70% chance the contract may expire worthless, offering a potential 1.11% return on cash commitment.
Call Contract Overview: The $21.00 call contract has a bid of $1.55, enabling investors to sell shares at that price, which represents a 3% premium over the current stock price. If the contract expires worthless, investors could keep both the shares and the premium, resulting in a 7.58% additional return.
Volatility Insights: The implied volatility for the put contract is 118%, while the call contract has an implied volatility of 99%. The actual trailing twelve-month volatility is calculated at 78%.
YieldBoost Concept: The article discusses the concept of YieldBoost, highlighting potential returns from both put and call contracts, and emphasizes the importance of tracking odds and trading history for informed investment decisions.
Immunome Prices 18.625M Share Offering at $21.50, Raising Approximately $400 Million
- Significant Fundraising: Immunome announced the pricing of 18.625 million shares at $21.50 each, raising approximately $400 million, which will enhance the company's financial strength to support its cancer therapy development.
- Underwriter Selection: The offering is managed by Leerink Partners, J.P. Morgan, TD Cowen, Goldman Sachs, and Guggenheim Securities, reflecting strong market confidence and support for Immunome.
- Additional Share Option: Immunome granted underwriters a 30-day option to purchase an additional 2.79375 million shares, potentially increasing total fundraising and enhancing the company's financial flexibility.
- Expected Closing Date: The offering is anticipated to close on December 18, 2025, subject to customary closing conditions, which will provide funding to accelerate the clinical development of its innovative therapies.
Immunome Prices 18.625M Shares at $21.50, Raising Approximately $400 Million
- Significant Fundraising: Immunome announced the pricing of 18.625 million shares at $21.50 each, raising approximately $400 million, which will provide crucial funding for its cancer therapy development and accelerate clinical project advancements.
- Underwriter Selection: The offering is managed by Leerink Partners, J.P. Morgan, TD Cowen, Goldman Sachs, and Guggenheim Securities, reflecting strong market confidence in Immunome and potentially enhancing its reputation in the biotechnology sector.
- Additional Share Option: Immunome granted underwriters a 30-day option to purchase an additional 2.79375 million shares, which, if exercised, could further increase total proceeds and enhance the company's financial flexibility to meet future R&D needs.
- Closing Timeline: The offering is expected to close on December 18, 2025, subject to customary closing conditions, providing investors with a clear timeline that may increase market interest in the company.
